The Journal of antimicrobial chemotherapy · 2026
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase-producing Gram-negative bacteria in a neutropenic murine thigh infection model.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Georgiou Panagiota-Christina, Siopi Maria, Tsala Marilena, Lagarde Claudia, Kloezen Wendy, Muller Anouk E, Meletiadis Joseph
Аннотация
BACKGROUND: Taniborbactam (VNRX-5133) is a novel boronate-based β-lactamase inhibitor that directly inhibits all four classes of β-lactamases. We studied the pharmacodynamics of taniborbactam in combination with cefepime against β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa.
METHODS: In vitro, cefepime/taniborbactam combination was assessed with a checkerboard broth microdilution method against two ESBL-producing Enterobacterales and one AmpC- and one VIM-producing P. aeruginosa isolates (cefepime MIC 16-256 mg/L). In vivo, neutropenic infected mice were treated with cefepime, every 2 h for 24 h, alone or in combination with taniborbactam at q2h, q4h and q8h dosing intervals. Single dose escalation and dose-fractionation experiments were conducted in order to describe plasma pharmacokinetics and pharmacodynamics of taniborbactam, respectively.
RESULTS: In vitro, reversal of phenotypic resistance to cefepime was found at taniborbactam ≤0.03 and 0.25 mg/L for ESBL-producing E. coli and K. pneumoniae, and at 0.125 and 2 mg/L for VIM- and AmpC constitutively-producing P. aeruginosa, respectively. In vivo, cefepime alone marginally reached stasis against Enterobacterales and AmpC-producing P. aeruginosa. Taniborbactam restored cefepime's static effect against all isolates and its 1 log10 kill effect against all strains except the K. pneumoniae isolate. The percentage of time above free concentration threshold (%fT > Ct) best described taniborbactam efficacy (R2 = 0.50-0.80). At high cefepime exposures, area under the free concentration-time curve (fAUC) performed equally well (R2 0.49-0.70). A 40%-50% and 60%-100% fT > Ct of taniborbactam was associated with stasis and 1 log10 kill, respectively, at taniborbactam concentrations where reversal of cefepime resistance was found in vitro.
CONCLUSIONS: Taniborbactam restored cefepime's activity against resistant Gram-negative bacteria in a time- and concentration-dependent manner at low and higher cefepime exposures, respectively.
METHODS: In vitro, cefepime/taniborbactam combination was assessed with a checkerboard broth microdilution method against two ESBL-producing Enterobacterales and one AmpC- and one VIM-producing P. aeruginosa isolates (cefepime MIC 16-256 mg/L). In vivo, neutropenic infected mice were treated with cefepime, every 2 h for 24 h, alone or in combination with taniborbactam at q2h, q4h and q8h dosing intervals. Single dose escalation and dose-fractionation experiments were conducted in order to describe plasma pharmacokinetics and pharmacodynamics of taniborbactam, respectively.
RESULTS: In vitro, reversal of phenotypic resistance to cefepime was found at taniborbactam ≤0.03 and 0.25 mg/L for ESBL-producing E. coli and K. pneumoniae, and at 0.125 and 2 mg/L for VIM- and AmpC constitutively-producing P. aeruginosa, respectively. In vivo, cefepime alone marginally reached stasis against Enterobacterales and AmpC-producing P. aeruginosa. Taniborbactam restored cefepime's static effect against all isolates and its 1 log10 kill effect against all strains except the K. pneumoniae isolate. The percentage of time above free concentration threshold (%fT > Ct) best described taniborbactam efficacy (R2 = 0.50-0.80). At high cefepime exposures, area under the free concentration-time curve (fAUC) performed equally well (R2 0.49-0.70). A 40%-50% and 60%-100% fT > Ct of taniborbactam was associated with stasis and 1 log10 kill, respectively, at taniborbactam concentrations where reversal of cefepime resistance was found in vitro.
CONCLUSIONS: Taniborbactam restored cefepime's activity against resistant Gram-negative bacteria in a time- and concentration-dependent manner at low and higher cefepime exposures, respectively.
Предметные рубрики MeSH
AnimalsCefepimeMicrobial Sensitivity TestsMiceAnti-Bacterial AgentsNeutropeniabeta-LactamasesDisease Models, AnimalPseudomonas aeruginosabeta-Lactamase InhibitorsBorinic AcidsFemaleDrug Therapy, CombinationThird Generation CephalosporinsBoronic AcidsEnterobacteriaceaeGram-Negative BacteriaGram-Negative Bacterial InfectionsEnterobacteriaceae InfectionsCarboxylic Acids